Mark Jaros
About
Mark Jaros is a scholar working on Surgery, Epidemiology and Neurology.
According to data from OpenAlex, Mark Jaros has authored 50 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Surgery, 16 papers in Epidemiology and 15 papers in Neurology. Recurrent topics in Mark Jaros's work include Parkinson's Disease Mechanisms and Treatments (9 papers), Restless Legs Syndrome Research (9 papers) and Sleep and Wakefulness Research (9 papers). Mark Jaros is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (9 papers), Restless Legs Syndrome Research (9 papers) and Sleep and Wakefulness Research (9 papers). Mark Jaros collaborates with scholars based in United States, United Kingdom and Germany. Mark Jaros's co-authors include Frederick J. Raal, Lawrence A. Leiter, David Kallend, R. Scott Wright, Wolfgang Köenig, Kausik K. Ray, John J.P. Kastelein, Peter Wijngaard, Lei Ling and Stephen J. Rossi and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.
In The Last Decade
Mark Jaros
46 papers receiving 3.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mark Jaros United States | 17 | 1.6k | 725 | 723 | 567 | 483 | 50 | 3.1k | ||
| Anne Grete Semb Norway | 37 | 831 0.5× | 715 1.0× | 454 0.6× | 148 0.3× | 141 0.3× | 146 | 4.7k | ||
| Angelo B. Cefalù Italy | 26 | 1.1k 0.7× | 411 0.6× | 370 0.5× | 896 1.6× | 66 0.1× | 129 | 2.5k | ||
| Jeffrey Kroon Netherlands | 31 | 1.3k 0.8× | 685 0.9× | 458 0.6× | 369 0.7× | 74 0.2× | 97 | 3.2k | ||
| Robert S. Rosenson United States | 14 | 936 0.6× | 223 0.3× | 348 0.5× | 183 0.3× | 223 0.5× | 22 | 2.8k | ||
| Linda Morrow United States | 29 | 1.1k 0.7× | 1.1k 1.5× | 881 1.2× | 1.8k 3.2× | 57 0.1× | 81 | 3.6k | ||
| Christoph H. Saely Austria | 32 | 852 0.5× | 775 1.1× | 747 1.0× | 834 1.5× | 79 0.2× | 203 | 3.4k | ||
| G Turpin France | 27 | 905 0.6× | 458 0.6× | 1.2k 1.6× | 1.6k 2.8× | 70 0.1× | 127 | 3.2k | ||
| Stephen D. Wiviott United States | 28 | 1.6k 1.0× | 656 0.9× | 205 0.3× | 1.4k 2.4× | 464 1.0× | 68 | 3.5k | ||
| Pi‐Jung Hsiao Taiwan | 29 | 661 0.4× | 569 0.8× | 538 0.7× | 606 1.1× | 37 0.1× | 84 | 2.1k | ||
| Bum‐Kee Hong South Korea | 28 | 1.8k 1.1× | 375 0.5× | 434 0.6× | 256 0.5× | 112 0.2× | 126 | 3.3k |
Countries citing papers authored by Mark Jaros
Since
Specialization
Citations
This map shows the geographic impact of Mark Jaros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Jaros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Jaros more than expected).
Fields of papers citing papers by Mark Jaros
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mark Jaros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Jaros. The network helps show where Mark Jaros may publish in the future.
Co-authorship network of co-authors of Mark Jaros
This figure shows the co-authorship network connecting the top 25 collaborators of Mark Jaros. A scholar is included among the top collaborators of Mark Jaros based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Jaros. Mark Jaros is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Rolan, Paul, Jonathan R. Seckl, Jack A. Taylor, et al.. (2025). Clinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System Disease. Clinical Pharmacology in Drug Development. 14(2). 105–115.
2.
Mazurek, M F, et al.. (2025). Epstein–Barr Virus (EBV) and Human Papilloma Virus (HPV) in Gastric Cancers, with Special Reference to Gastric Cancer at a Young Age—A Pilot Study in Poland. International Journal of Molecular Sciences. 26(2). 711–711.
3.
O’Connor, Susan, et al.. (2024). BNC210, an α7 Nicotinic Receptor Modulator, in Post-Traumatic Stress Disorder. NEJM Evidence. 4(1). EVIDoa2400380–EVIDoa2400380.
4.
Colquhoun, David, R. Scott Wright, Kausik K. Ray, et al.. (2023). Efficacy and Safety of Inclisiran According to Age: A Pooled Analysis of Phase III Studies (ORION 9, 10 and 11). Heart Lung and Circulation. 32. S387–S387.
5.
Ray, Kausik K., Frederick J. Raal, David Kallend, et al.. (2022). Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. European Heart Journal. 44(2). 129–138.
6.
Okuda, Darin T., et al.. (2022). Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial. Brain Communications. 4(6). fcac300–fcac300.
7.
Landmesser, Ulf, Kausik K. Ray, Frederick J. Raal, et al.. (2021). EFFICACY AND SAFETY OF INCLISIRAN IN PATIENTS WITH CHRONIC KIDNEY DISEASE - A POOLED ANALYSIS FROM THREE PHASE 3 CLINICAL TRIALS (ORION-9, -10 AND -11). Journal of the American College of Cardiology. 77(18). 1458–1458.
8.
Ray, Kausik K., R. Scott Wright, David Kallend, et al.. (2020). Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. New England Journal of Medicine. 382(16). 1507–1519.
9.
Ray, Kausik K., Frederick J. Raal, David Kallend, et al.. (2020). Abstract 16311: Efficacy and Safety of Inclisiran According to Sex: A Pooled Analysis of the ORION 9, 10 and 11 Trials. Circulation. 142(Suppl_3).
10.
Hirschfield, Gideon M., Olivier Chazouillères, Joost P.H. Drenth, et al.. (2018). Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. Journal of Hepatology. 70(3). 483–493.
11.
Gidal, Barry E., et al.. (2016). Impact of Data Imputation Methodology on Pain Assessment over 24 Hours in a Randomized, Placebo-Controlled Study of Gabapentin Enacarbil in Patients with Neuropathic Pain Associated with Postherpetic Neuralgia. Pain Medicine. 17(4). 728–736.
12.
Hermanowicz, Neal, Aaron Ellenbogen, Gordon Irving, et al.. (2016). The Effect of Gabapentin Enacarbil on Pain Associated with Moderate-to-Severe Primary Restless Legs Syndrome in Adults: Pooled Analyses from Three Randomized Controlled Trials. CNS Drugs. 30(5). 443–454.
13.
Ahmed, Mansoor M., et al.. (2016). Effect of Gabapentin Enacarbil on Individual Items of the International Restless Legs Study Group Rating Scale and Post-sleep Questionnaire in Adults with Moderate-to-Severe Primary Restless Legs Syndrome: Pooled Analysis of 3 Randomized Trials. Clinical Therapeutics. 38(7). 1726–1737.e1.
14.
Avidan, Alon Y., et al.. (2016). The Effect of Gabapentin Enacarbil on Quality of Life and Mood Outcomes in a Pooled Population of Adult Patients with Moderate-to-Severe Primary Restless Legs Syndrome. CNS Drugs. 30(4). 305–316.
15.
Laham, Roger J., et al.. (2015). (392) Weight change in adults with postherpetic neuralgia receiving gabapentin enacarbil in a randomized, placebo-controlled trial. Journal of Pain. 16(4). S74–S74.
16.
Avidan, Alon Y., et al.. (2015). The Effect of Gabapentin Enacarbil (GEn) on Quality-of-Life (QoL) Outcomes in Adult Patients With Moderate-to-Severe and Severe Primary Restless Legs Syndrome (RLS): Pooled Analyses From Two 12-Week Trials (P7.299). Neurology. 84(14_supplement).
17.
Hermanowicz, Neal, et al.. (2015). The Effect of Gabapentin Enacarbil (GEn) on Pain Outcomes in Adults with Moderate-to-Severe and Severe Primary Restless Legs Syndrome (RLS): Pooled Analyses from 3 Randomized Controlled Trials (P7.294). Neurology. 84(14_supplement).
18.
Altman, Roy D., Marc C. Hochberg, Allan Gibofsky, Mark Jaros, & Clarence L. Young. (2015). Efficacy and safety of low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: a 12-week, phase 3 study. Current Medical Research and Opinion. 31(12). 2331–2343.
19.
Cedarbaum, Jesse M., Mark Jaros, C. Hernandez, et al.. (2012). Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials. Alzheimer s & Dementia. 9(1S). S45–55.
20.
Jaros, Mark, et al.. (2012). Clinical evaluation of XaraColl®, a bupivacaine-collagen implant, for postoperative analgesia in two multicenter, randomized, double-blind, placebo-controlled pilot studies. Journal of Pain Research. 5. 217–217.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Anne Grete Semb Breakdown of academic impact, for papers by Angelo B. Cefalù Breakdown of academic impact, for papers by Jeffrey Kroon Breakdown of academic impact, for papers by Robert S. Rosenson Breakdown of academic impact, for papers by Linda Morrow Breakdown of academic impact, for papers by Christoph H. Saely Breakdown of academic impact, for papers by G Turpin Breakdown of academic impact, for papers by Stephen D. Wiviott Breakdown of academic impact, for papers by Pi‐Jung Hsiao Breakdown of academic impact, for papers by Bum‐Kee Hong